Abstract

Pathogenic trypanosomatids (Trypanosoma cruzi, Trypanosoma brucei, and Leishmania spp.) are protozoan parasites that cause neglected diseases affecting millions of people in Africa, Asia, and the Americas. In the process of infection, trypanosomatids evade and survive the immune system attack, which can lead to a chronic inflammatory state that induces cumulative damage, often killing the host in the long term. The immune mediators involved in this process are not entirely understood. Most of the research on the immunologic control of protozoan infections has been focused on acute inflammation. Nevertheless, when this process is not terminated adequately, permanent damage to the inflamed tissue may ensue. Recently, a second process, called resolution of inflammation, has been proposed to be a pivotal process in the control of parasite burden and establishment of chronic infection. Resolution of inflammation is an active process that promotes the normal function of injured or infected tissues. Several mediators are involved in this process, including eicosanoid-derived lipids, cytokines such as transforming growth factor (TGF)-β and interleukin (IL)-10, and other proteins such as Annexin-V. For example, during T. cruzi infection, pro-resolving lipids such as 15-epi-lipoxin-A4 and Resolvin D1 have been associated with a decrease in the inflammatory changes observed in experimental chronic heart disease, reducing inflammation and fibrosis, and increasing host survival. Furthermore, Resolvin D1 modulates the immune response in cells of patients with Chagas disease. In Leishmania spp. infections, pro-resolving mediators such as Annexin-V, lipoxins, and Resolvin D1 are related to the modulation of cutaneous manifestation of the disease. However, these mediators seem to have different roles in visceral or cutaneous leishmaniasis. Finally, although T. brucei infections are less well studied in terms of their relationship with inflammation, it has been found that arachidonic acid-derived lipids act as key regulators of the host immune response and parasite burden. Also, cytokines such as IL-10 and TGF-β may be related to increased infection. Knowledge about the inflammation resolution process is necessary to understand the host–parasite interplay, but it also offers an interesting opportunity to improve the current therapies, aiming to reduce the detrimental state induced by chronic protozoan infections.

Highlights

  • Specialty section: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Microbiology

  • Acetylsalicylic acid (ASA)-acetylated cyclooxygenase 2 (COX-2) produces 5-RHydroxyeicosatetraenoic acid (5-RHETE) from arachidonic acid (AA). 5-RHETE is a substrate of 5-LO that can be converted to 15-epi-lipoxin A4 (15-epi-LXA4), which is named acetylsalicylic acid (ASA)-triggered lipoxin (ATL) (Serhan, 2005)

  • The actions of LXA4 are mediated by a GPCR called formyl peptide receptor 2/lipoxin A4 receptor (FPR2/ALXR), via several signaling pathways, including the p38/mitogen-activated protein kinase (MAPK)-activated protein kinase (APK)/heat shock protein 27 (HSP27), c-Jun N-terminal kinase (JNK), and phosphatidylinositol 3-kinase (PI3K) pathways (Cooray et al, 2013), depending on the cell type

Read more

Summary

SPMs Synthesis

Lipoxins Lipoxins are eicosanoids derived from omega-6 arachidonic acid (AA), which is oxygenated at position 15 by 15-LO activity to produce 15S-hydroperoxyeicosatetraenoic acid (15S-H(p)ETE). Acetylsalicylic acid (ASA)-acetylated cyclooxygenase 2 (COX-2) produces 5-RHydroxyeicosatetraenoic acid (5-RHETE) from AA. 5-RHETE is a substrate of 5-LO that can be converted to 15-epi-lipoxin A4 (15-epi-LXA4), which is named ASA-triggered lipoxin (ATL) (Serhan, 2005). Resolvins On the other hand, Rvs, PDs, and maresins are derived from omega-3 polyunsaturated fatty acids. The RvD1–4 series, as well as PDs and maresins, are derived from docosahexaenoic acid (DHA) metabolism involving 12-LO and 15-LO, and the E-series Rvs are derived from the activity of ASA-acetylated COX-2 using eicosapentaenoic acid (EPA) as a substrate (Serhan, 2007). 5-LO can covert to ASA-triggered Resolvin D1–4 (AT-RvD1–4) (Serhan, 2007)

Drug Induction of SPMs
The Inflammation Resolution Crossroad
SPMs Mode of Action
Physiologic Actions of SPMs
Role of SPMs in Chronic Infectious Diseases
Trypanosoma cruzi INFECTIONS
Role of SPMs in Acute Chagas Disease
Acetylsalicylic Acid in Acute and Chronic Chagas Disease
Cutaneous Leishmaniasis
PBMC from patients with Chagas disease
Visceral leishmaniasis
Visceral Leishmaniasis
Trypanosoma brucei INFECTIONS
Findings
CONCLUDING REMARKS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call